Merck & Co., Inc.  

(Public, NYSE:MRK)   Watch this stock  
Find more results for MRK
55.01
+0.96 (1.78%)
Real-time:   2:42PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 54.32 - 55.11
52 week 44.62 - 61.33
Open 54.57
Vol / Avg. 10.20M/10.67M
Mkt cap 156.24B
P/E 29.00
Div/yield 0.44/3.20
EPS 1.90
Shares 2.90B
Beta 0.34
Inst. own 75%
Oct 27, 2014
Q3 2014 Merck & Co Inc Earnings Release - 9:30AM EDT - Add to calendar
Oct 27, 2014
Q3 2014 Merck & Co Inc Earnings Call - 8:00AM EDT - Add to calendar
Sep 22, 2014
Merck & Co Inc at EBD Group BioPharm America
Sep 9, 2014
Merck & Co Inc at Morgan Stanley Healthcare Conference - Webcast
Jul 29, 2014
Q2 2014 Merck & Co., Inc. Earnings Release
Jul 29, 2014
Q2 2014 Merck & Co Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 18.59% 10.26%
Operating margin 11.35% 13.53%
EBITD margin - 52.74%
Return on average assets 7.90% 4.27%
Return on average equity 16.35% 8.57%
Employees 76,000 -
CDP Score - 87 B

Address

1 Merck Dr PO Box 100
WHITEHOUSE STATION, NJ 08889-0100
United States - Map
+1-908-4231000 (Phone)
+1-908-4231987 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Merck & Co., Inc. (Merck), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. On July 2, 2014, Santen Pharmaceutical Co., Ltd acquired certain ophthalmology assets from Merck & Co., Inc. On August 5, 2014, Merck & Co Inc (Merck) acquired Idenix Pharmaceuticals Inc (Idenix).

Officers and directors

Kenneth C. Frazier Chairman of the Board, President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert M. Davis Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Clark Golestani Executive Vice President, Chief Information Officer
Age: 47
Bio & Compensation  - Reuters
Michael J. Holston Executive Vice President, Chief Ethics and Compliance Officer
Age: 51
Bio & Compensation  - Reuters
Bruce N. Kuhlik Executive Vice President, General Counsel
Age: 57
Bio & Compensation  - Reuters
Mirian M. Graddick-Weir Executive Vice President - Human Resources
Age: 59
Bio & Compensation  - Reuters
Willie A Deese Executive Vice President, President - Merck Manufacturing Division
Age: 58
Bio & Compensation  - Reuters
Richard R. DeLuca Jr. Executive Vice President, President - Merck Animal Health
Age: 51
Bio & Compensation  - Reuters
Cuong Viet Do Executive Vice President, Chief Strategy Officer
Age: 47
Bio & Compensation  - Reuters
Bridgette P. Heller Executive Vice President, President - Merck Consumer Care
Age: 52
Bio & Compensation  - Reuters